




RealRate

# PHARMACEUTICAL 2019

Myovant Sciences Ltd.  
Rank 300 of 371



RealRate

• Financial Strength Rankings using Artificial Intelligence

• [www.realrate.ai](http://www.realrate.ai)



# PHARMACEUTICAL 2019

Myovant Sciences Ltd.  
Rank 300 of 371

The relative strengths and weaknesses of Myovant Sciences Ltd. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Myovant Sciences Ltd. compared to the market average is the variable Other Liabilities, increasing the Economic Capital Ratio by 53% points. The greatest weakness of Myovant Sciences Ltd. is the variable Research and Development, reducing the Economic Capital Ratio by 285% points.

The company's Economic Capital Ratio, given in the ranking table, is -539%, being 208% points below the market average of -331%.

Input Variable	Value in 1000 USD
Assets, Current	114,763
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	37,085
Liabilities, Non-Current	0
Other Assets	3,065
Other Compr. Net Income	-116
Other Expenses	2,259
Other Liabilities	44,287
Other Net Income	67
Property and Equipment	1,273
Research and Development	116,832
Revenues	0
Selling, General and Administrative Expense	24,231

Output Variable	Value in 1000 USD
Assets	119,101
Liabilities	81,372
Expenses	143,322
Stockholders Equity	37,729
Net Income	-143,255
Comprehensive Net Income	-143,313
Economic Capital Ratio	-539%

